DrugPatentWatch Database Preview
UNIVASC Drug Profile
see a sample report or, see our see our flat-rate plans
Which patents cover Univasc, and what generic alternatives are available?
The generic ingredient in UNIVASC is moexipril hydrochloride. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the moexipril hydrochloride profile page.
Summary for UNIVASC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 31 |
| Clinical Trials: | 2 |
| Patent Applications: | 3,299 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for UNIVASC |
| DailyMed Link: | UNIVASC at DailyMed |
Pharmacology for UNIVASC
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Synonyms for UNIVASC
| (3S)-2-((2S)-N-((1S)-1-Carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, 2-ethyl ester, monohydrochloride |
| (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenyl-d5-propyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic Acid Hydrochloride |
| (3S)-2-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid hydrochloride |
| (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid hydrochloride |
| (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid;hydrochloride |
| (S)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride |
| 2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride |
| 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (3S-(2(R*(R*)),3R*))- |
| 3-isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-((1-ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, monohydrochloride, (3S-(2(R*(R*)),3R*))- |
| 3-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-, monohydrochloride, (3S-(2(R*(R*)),3R*))- |
| 586M525 |
| 82586-52-5 |
| AB2000483 |
| AC1L1HXF |
| AKOS016340373 |
| Ambap103775-10-6 |
| AN-36120 |
| API0003416 |
| BS-1007 |
| C27H34N2O7.HCl |
| CAS-82586-52-5 |
| CHEBI:6961 |
| CHEMBL1200534 |
| CI 925 |
| CI-925 |
| CS-2446 |
| CTK8G1159 |
| D00623 |
| DSSTox_CID_24267 |
| DSSTox_GSID_44267 |
| DSSTox_RID_80137 |
| DTXSID7044267 |
| Femipres |
| HY-B0378A |
| JXRAXHBVZQZSIC-JKVLGAQCSA-N |
| LS-85469 |
| MLS003882580 |
| Moexipril (hydrochloride) |
| Moexipril HCL |
| MOEXIPRIL HYDROCHLORIDE |
| Moexipril hydrochloride (USAN) |
| Moexipril hydrochloride [USAN] |
| Moexipril hydrochloride, powder, >=98% (HPLC) |
| Moexipril hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| MolPort-003-666-743 |
| NCGC00167834-01 |
| NCGC00263546-01 |
| Perdix |
| Primoxil |
| Q1UMG3UH45 |
| RS 10085 |
| RS 10085-197 |
| RS-10085 |
| RS-10085-197 |
| s2079 |
| SC-95143 |
| SCHEMBL40877 |
| SMR002533645 |
| SPM 925 |
| SPM-925 |
| Tox21_112590 |
| Tox21_112590_1 |
| UNII-Q1UMG3UH45 |
| Univasc (TN) |
US Patents and Regulatory Information for UNIVASC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-001 | Apr 19, 1995 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for UNIVASC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | ➤ Sign Up | ➤ Sign Up |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-001 | Apr 19, 1995 | ➤ Sign Up | ➤ Sign Up |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-002 | Apr 19, 1995 | ➤ Sign Up | ➤ Sign Up |
| Ucb Inc | UNIVASC | moexipril hydrochloride | TABLET;ORAL | 020312-001 | Apr 19, 1995 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
see a sample report or, see our see our flat-rate plans
